go-v.orgcodex
Menu
Page tools

codex · Chemistry

Bleximenib

Diagram for Bleximenib
Bleximenib is an investigational new drug that is being evaluated by Janssen Research & Development for the treatment of acute myeloid leukaemia (AML). It is a menin inhibitor preventing its interaction with KMT2A. · image: Wikimedia Commons

Bleximenib is an investigational new drug that is being evaluated by Janssen Research & Development for the treatment of acute myeloid leukaemia (AML). It is a menin inhibitor preventing its interaction with KMT2A.

== Pharmacology == Bleximenib is a selective inhibitor of menin preventing its interaction with the lysine methyltransferase KMT2A. The menin/KMT2A complex regulates gene expression in leukemia cells which keeps them in an immature state that is continually dividing.

== Clinical trials == Bleximenib is in phase 3 clinical trials for AML.

== References ==

Wikipedia contributors, "Bleximenib", Wikipedia, revision 1385145168, retrieved 21 November 2026, source, CC BY-SA 4.0.

More Chemistry · Search the codex